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Ambiguous gene names impose a serious
hurdle for the analysis of a wide range of
high-throughput data, such as micro-
array experiments or protein-interaction
maps. This sort of ambiguity also limits
the efficiency of genome analysis and
annotation and slows the implementa-
tion of automatic text-mining systems
for using bibliographic information [1,2].
While systems for automatic gene name
recognition in other domains (such as in
business or news reports) perform very
well, the best systems in the biological
field perform just slightly better than
80% [3]. 
Genes are commonly named using
functional terms, such as ‘insulin’ or
‘tumor necrosis factor’, or symbols con-
sisting of abbreviations such as INS for
insulin or TNF for tumor necrosis
factor. Functional names are usually
unique, in the sense that a given name
refers only to one gene family, even if
not always to a single gene of the
family. Ambiguity exists because often
more than one functional name is used
to refer to the same gene (synonymy),
and also many functional names are
descriptive of some phenotype of the
gene (such as ‘deafness’ or ‘wingless’),
a practice that creates many complica-
tions [4]. The use of symbols should
alleviate some of the problems created
by the use of functional names, but in
practice seems to produce even more
ambiguities. In addition to extended
synonymy (with many symbols
describing the same gene), a given
symbol can also be used to describe dif-
ferent genes (homonymy). Moreover,
many other meanings can match the
abbreviation used for the gene name
(acronyms). Text-mining systems are
severely limited by these factors, as
ambiguities decrease the precision in
the retrieval of correct articles, and
synonyms limit the number of total
retrieved articles.  
These limitations potentially impair the
effective application of text mining and
natural language processing (NLP)
techniques in genomics. For instance,
the comparison of microarray data from
different sources requires the exact
mapping of the names used by different
authors. This task can be greatly com-
plicated by ambiguous names such as
‘PAP’, which can refer to five different
human genes, and will therefore be
impossible to classify in the absence of
additional information. In this type of
situation, valuable experimental infor-
mation could be lost because of nomen-
clature problems that could be solved
by the use of standard names.
Standard nomenclatures, strictly fol-
lowing naming guidelines, are the most
obvious solution to the problem.
Indeed, considerable community effort
has gone into the creation of these
standards for gene symbols in organ-
isms such as yeast, mouse, fly, and, of
course, human. An illustrative example
is the valuable effort of HUGO nomen-
clature for human genes [5,6]. A single
official symbol is proposed for every
gene, and the aliases (alternative
symbols, synonyms) for each gene are
also listed. The obvious concern is the
extent to which scientists follow these
nomenclature rules. Other instances
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Abstract
Current usage of gene nomenclature is ambiguous and impairs the efficient handling of scientific
information. Therefore it is important to propose guidelines to deal with this problem. This study
attempts to evaluate the success of HUGO nomenclature for human genes. The results indicate
that HUGO guidelines are not supported by the scientific community.of standard nomenclatures, such as
enzymatic codes (EC numbers), have
been loosely followed.
We carried out a study to assess the
relative success of HUGO guidelines by
measuring the progress in the usage of
official gene symbols in recent years.
We analyzed PubMed abstracts for the
period 1994-2004, collecting informa-
tion regarding the mention of human
gene symbols and the frequency with
which official symbols were mentioned
in comparison with their aliases. It is
painfully obvious that the community
has not widely adopted the HUGO
guidelines. It is equally obvious that
there is no clear tendency that this sit-
uating is improving, as the proportion
of official symbols that are used pre-
dominantly has only increased slightly,
from 35% in 1994 to 44% in 2004
(Figure 1). Accordingly, a small
decrease in the cases where the official
name was not mentioned at all is
observed (from 23% in 1994 to 14% in
2004). Despite this minor progress, it
is still true that aliases are used more
often than official symbols, and as
many as 14% of genes are never men-
tioned using the recommended official
symbols.
A positive observation is that this small
increment is in part due to new genes
that are named preferentially according
to the official standards. The genes
mentioned for the first time after the
year 2000 have a higher proportion of
official symbols and a smaller number
of synonyms (Figure 1); however, it can
still be argued that it is only a question
of time for these genes to acquire new
synonyms. Furthermore, highly refer-
enced genes are cited notably more
often by unofficial gene names. For
example, in 2004, only 38% of genes
cited in more than 50 articles were
named predominantly by following
HUGO, whereas scarcely cited genes
more often followed the standards
(54% in 2004).
The tendency to improve the situation
by replacing aliases in favor of HUGO
official symbols is, unfortunately, weak.
The changes in name usage, either
from official to aliases or from aliases
to official, are not very frequent, and
the nomenclature of most genes
remains rather stable with time. These
findings seem to confirm the intuition
that researchers remain attached to
their favorite names. 
This trend is not species-dependent.
For example, in yeast, where there is
also a proposed standard nomenclature
[7], there is not a tendency to replace
aliases with official names (the usage of
official names has remained approxi-
mately the same in recent years as in
the past), even if in this community
official names are used more often
(85% of the genes are preferentially
cited using official names). 
Many of the occasional transitions are
in fact produced after the publication of
a prominent paper describing an
important discovery regarding a gene,
which usually produces a chain of sub-
sequent studies that tend to use the new
name. For instance, in the mid-1990s
the gene for intestinal trefoil factor 3
was cited predominantly under the alias
ITF. But since 1998, the official name
TFF3 has been preferred, apparently
influenced by a paper describing the
regulation that the gene exerts on the
expression of catenin and  cadherin,
with important consequences for
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Figure 1
Usage of HUGO nomenclature in the past ten years. We analyzed PubMed abstracts for the period
1994-2004, collecting information about the human genes mentioned on the abstracts, and noting
how such mention was made (official symbol or other aliases). Names were detected using Text
Detective (BioAlma SL), a gene name recognition software that is able to recognize human gene
names in texts with high recall and precision, distinguishing real instances of the gene from other
uses and meanings of the same name [13]. Text Detective combines gene name recognition with
standardization of citations, using HUGO nomenclature in the case of human genes. Additional
results (the yeast results discussed in the text) were obtained using the Information Interlinked Over
Proteins (iHOP) system [14] in order to discard possible biases due to the name-recognition
software used. The percentage of genes that are cited predominantly by their official name is used as
a measure of the support for official names. Blue bars show the percentage of genes for which the
official name is favored (the official name is mentioned more often than aliases). Yellow bars show
the inverse, the percentage of genes for which aliases are favored. Green bars show the percentage
of cases in which the official name is never used, and all mentions correspond to aliases. Also, the
average number of names per gene is shown, computed as the total number of names used divided
by the total number of genes. The last column, labeled ‘Novel’, takes into account only those genes
whose first mention in the literature occurred in the year 2000 or later.
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Average names per geneepithelial cell adhesion, migration, and
survival [8], which gave rise to the use
of the symbol TFF3 for that gene.
Therefore, it would appear that impor-
tant scientific papers influence nomen-
clature usage even more than does the
adoption of standards (Figure 2a).
A similar case is illustrated in Figure
2b for the gene encoding the poliovirus
receptor. In the mid-1990s, the only
symbol used was PVR (which is today
the official name for the gene). The
alternative name CD155 for the protein
appeared for the first time in 1997, but
gained greater acceptance after the
publication in the late nineties of
several articles describing structural
aspects of the CD155 protein [9] that
are critical to the interaction with the
virus (CD nomenclature for cell-
surface proteins follows a long estab-
lished standard nomenclature). These
articles named the gene as CD155, and
this has been the preferred name since
then. In this case, HUGO nomencla-
ture apparently did not take this fact
into account, since the establishment
of PVR as the official gene name took
place in 2003. 
Finally, Figure 2c shows an interesting
case of the persistence of several differ-
ent names for one gene, that for the
chemokine lymphotactin. The cloning
of this gene was reported almost simul-
taneously by three independent groups
in Japan, Germany and the USA in
1995 [10-12]. The three groups named
the gene differently (SCM1, ATAC and
LTN, respectively). These names have
all been used since then, as well as
LPTN and, lately, the official name
XCL1. It is interesting to notice that the
three groups reporting the discovery
kept using their own names for the
gene, at least until very recently, a
trend that can be observed also in the
previous examples.
The problem of linking names in texts
with the molecules they refer to can
only be solved by a concerted commu-
nity effort to explicitly mention the offi-
cial names and/or the corresponding
database accession numbers (such as
these of UniProt or Refseq for proteins,
and GenBank for genes). The use of
accession numbers has the advantage
of providing a unique and unambigu-
ous reference that is also a direct link to
the real biological object. But it does
have some drawbacks. Citing accession
numbers instead of gene or protein
names would seriously affect the clarity
and readability of the text. From this
point of view, names and accession
numbers must coexist. This could be
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Figure 2
Plot of the evolution of the usage of different names. The plots show, for each year, the percentage
usage of each of the names. (a) Intestinal trefoil factor 3 (official name, TFF3); (b) poliovirus receptor
(official name, PVR); (c) lymphotactin (official name, XCL1).
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(c)done, for instance, by citing only names
in the main text, and including acces-
sion numbers for the protein or gene
names used in the text in a separate
section. Also, our experience is that
mapping between different databases is
not exempt from problems. For
instance, a single nucleotide sequence
often has several different entries, cor-
responding to splice variants, polymor-
phisms or regions of the genome. Also,
for these references to be really useful,
they would have to cover all the
mentions of genes including anaphoric
(the use of a linguistic unit, such as the
pronoun ‘it’ to refer to a previous
mention of the name) and other forms
of implicit mentions, and to take into
account the difference between individ-
ual genes and proteins and general
protein names referring to, for instance,
protein familes (that is, ‘tubulin beta1
protein’ can be assigned to a well
defined molecule, but ‘tubulin’ cannot,
since it can refer to several different
molecules). It would be important to
develop adequate tools to facilitate the
introduction of names and identifiers at
the time of writing papers, and to
enable the posterior recovery by both
humans and software tools. 
The task of tagging genes and proteins
in papers with the corresponding offi-
cial names and/or database entries will
require the collaboration of authors,
journals and grant agencies, and could
be facilitated by the development of
adequate text-mining methods.
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